These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1548 related articles for article (PubMed ID: 33882206)

  • 1. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    Bardia A; Hurvitz SA; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Sardesai SD; Kalinsky K; Zelnak AB; Weaver R; Traina T; Dalenc F; Aftimos P; Lynce F; Diab S; Cortés J; O'Shaughnessy J; Diéras V; Ferrario C; Schmid P; Carey LA; Gianni L; Piccart MJ; Loibl S; Goldenberg DM; Hong Q; Olivo MS; Itri LM; Rugo HS;
    N Engl J Med; 2021 Apr; 384(16):1529-1541. PubMed ID: 33882206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Vahdat LT; Tolaney SM; Isakoff SJ; Diamond JR; O'Shaughnessy J; Moroose RL; Santin AD; Abramson VG; Shah NC; Rugo HS; Goldenberg DM; Sweidan AM; Iannone R; Washkowitz S; Sharkey RM; Wegener WA; Kalinsky K
    N Engl J Med; 2019 Feb; 380(8):741-751. PubMed ID: 30786188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Diamond JR; Moroose RL; Isakoff SJ; Starodub AN; Shah NC; O'Shaughnessy J; Kalinsky K; Guarino M; Abramson V; Juric D; Tolaney SM; Berlin J; Messersmith WA; Ocean AJ; Wegener WA; Maliakal P; Sharkey RM; Govindan SV; Goldenberg DM; Vahdat LT
    J Clin Oncol; 2017 Jul; 35(19):2141-2148. PubMed ID: 28291390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
    Seligson JM; Patron AM; Berger MJ; Harvey RD; Seligson ND
    Ann Pharmacother; 2021 Jul; 55(7):921-931. PubMed ID: 33070624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2- Breast Cancer.
    Kang C
    Target Oncol; 2024 Mar; 19(2):289-296. PubMed ID: 38446351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
    Weiss J; Glode A; Messersmith WA; Diamond J
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
    [No Abstract]   [Full Text] [Related]  

  • 7. Sacituzumab Govitecan: First Approval.
    Syed YY
    Drugs; 2020 Jul; 80(10):1019-1025. PubMed ID: 32529410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
    Furlanetto J; Marmé F; Loibl S
    Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer.
    Wahby S; Fashoyin-Aje L; Osgood CL; Cheng J; Fiero MH; Zhang L; Tang S; Hamed SS; Song P; Charlab R; Dorff SE; Ricks TK; Barnett-Ringgold K; Dinin J; Goldberg KB; Theoret MR; Pazdur R; Amiri-Kordestani L; Beaver JA
    Clin Cancer Res; 2021 Apr; 27(7):1850-1854. PubMed ID: 33168656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
    O'Shaughnessy J; Brufsky A; Rugo HS; Tolaney SM; Punie K; Sardesai S; Hamilton E; Loirat D; Traina T; Leon-Ferre R; Hurvitz SA; Kalinsky K; Bardia A; Henry S; Mayer I; Zhu Y; Phan S; Cortés J
    Breast Cancer Res Treat; 2022 Sep; 195(2):127-139. PubMed ID: 35545724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
    Bardia A; Rugo HS; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Kalinsky K; Cortés J; Shaughnessy JO; Diéras V; Carey LA; Gianni L; Piccart-Gebhart M; Loibl S; Yoon OK; Pan Y; Hofsess S; Phan SC; Hurvitz SA
    J Clin Oncol; 2024 May; 42(15):1738-1744. PubMed ID: 38422473
    [No Abstract]   [Full Text] [Related]  

  • 12. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
    Schreiber AR; Andress M; Diamond JR
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524
    [No Abstract]   [Full Text] [Related]  

  • 13. First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
    Starodub AN; Ocean AJ; Shah MA; Guarino MJ; Picozzi VJ; Vahdat LT; Thomas SS; Govindan SV; Maliakal PP; Wegener WA; Hamburger SA; Sharkey RM; Goldenberg DM
    Clin Cancer Res; 2015 Sep; 21(17):3870-8. PubMed ID: 25944802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
    Rugo HS; Bardia A; Marmé F; Cortes J; Schmid P; Loirat D; Trédan O; Ciruelos E; Dalenc F; Pardo PG; Jhaveri KL; Delaney R; Fu O; Lin L; Verret W; Tolaney SM
    J Clin Oncol; 2022 Oct; 40(29):3365-3376. PubMed ID: 36027558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
    Bardia A; Tolaney SM; Punie K; Loirat D; Oliveira M; Kalinsky K; Zelnak A; Aftimos P; Dalenc F; Sardesai S; Hamilton E; Sharma P; Recalde S; Gil EC; Traina T; O'Shaughnessy J; Cortes J; Tsai M; Vahdat L; Diéras V; Carey LA; Rugo HS; Goldenberg DM; Hong Q; Olivo M; Itri LM; Hurvitz SA
    Ann Oncol; 2021 Sep; 32(9):1148-1156. PubMed ID: 34116144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
    Fenn KM; Kalinsky K
    Drugs Today (Barc); 2019 Sep; 55(9):575-585. PubMed ID: 31584574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
    Goldenberg DM; Sharkey RM
    MAbs; 2019; 11(6):987-995. PubMed ID: 31208270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacituzumab govitecan (Trodelvy) for metastatic triple-negative breast cancer.
    Med Lett Drugs Ther; 2021 Feb; 63(1617):e25-e27. PubMed ID: 33757114
    [No Abstract]   [Full Text] [Related]  

  • 19. TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.
    Petrylak DP; Tagawa ST; Jain RK; Bupathi M; Balar A; Kalebasty AR; George S; Palmbos P; Nordquist L; Davis N; Ramamurthy C; Sternberg CN; Loriot Y; Agarwal N; Park C; Tonelli J; Vance M; Zhou H; Grivas P
    J Clin Oncol; 2024 Oct; 42(29):3410-3420. PubMed ID: 39186707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.
    Bardia A; Hurvitz SA; Rugo HS; Brufsky A; Cortes J; Loibl S; Piccart M; Cowden J; Spears P; Carey LA
    Future Oncol; 2021 Oct; 17(30):3911-3924. PubMed ID: 34467774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 78.